MindWalk Holdings Corp.

ImmunoPrecise Antibodies Ltd. was incorporated on September 2, 2016, under the Business Corporations Act (British Columbia), changing its name to ImmunoPrecise Antibodies Ltd. on December 21, 2016. The company's head office is located at Industrious 823 Congress Ave Suite 300 Austin, Texas 78701, with its registered and records office at 19th Floor, 885 West Georgia Street, Vancouver, British Columbia V6B0M3V6C 3H4, Canada. Its business activities are conducted through wholly-owned subsidiaries. ImmunoPrecise Antibodies Ltd.'s Common Shares are listed and traded on Nasdaq under the symbol "IPA." Over the last three years, the company has focused on expanding its service and product offerings and increasing revenues through both organic growth and acquisitions. Key management changes in the fiscal year ended 2023 include Ms. Lisa Helbling's retirement as Chief Financial Officer (CFO) in August 2022, followed by Mr. Brad McConn's appointment as CFO effective August 6, 2022. In November 2022, Dr. Anna Pettersson did not stand for re-election due to a potential conflict of interest. In December 2022, Ms. Lisa Helbling was appointed as a director. On October 12, 2022, the company's subsidiary, Talem, entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated.